Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.

@article{Mark2000CosteffectivenessOP,
  title={Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.},
  author={Daniel B. Mark and Robert A. Harrington and Abraham Michael Lincoff and Robert M. Califf and Charlotte L. Nelson and Anastasios A. Tsiatis and Hope E. Buell and Kenneth W. Mahaffey and Linda D Davidson-Ray and Eric J. Topol},
  journal={Circulation},
  year={2000},
  volume={101 4},
  pages={366-71}
}
BACKGROUND In the PURSUIT trial, eptifibatide significantly reduced the 30-day incidence of death and myocardial infarction relative to placebo in 9461 patients with an acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction). METHODS AND RESULTS We conducted a 2-part prospective economic substudy of the 3522 US patients enrolled in PURSUIT: (1) an empirical intention-to-treat comparison of medical costs (hospital plus physician) up to 6 months after hospitalization and… CONTINUE READING